Lantheus Holdings, Inc. (LNTH): EBITDA
$380.93M
Year ended 2025-12-31
$390.85M
Trailing 12 months to 2026-06-30
+65.4%
3-year compound annual growth
+79.4%
5-year compound annual growth
+19.9%
10-year compound annual growth
| Period ended | EBITDA | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | $380.93M | -27.0% | 2026-02-26, From 2025-01-01 |
| 2024-12-31 | $521.60M | +22.8% | 2026-02-26, From 2024-01-01 |
| 2023-12-31 | $424.69M | +404.8% | 2026-02-26, From 2023-01-01 |
| 2022-12-31 | $84.12M | n/m | 2025-02-26, From 2022-01-01 |
| 2021-12-31 | -$18.54M | n/m | 2024-02-22, From 2021-01-01 |
| 2020-12-31 | $20.49M | -68.5% | 2023-02-23, From 2020-01-01 |
| 2019-12-31 | $65.04M | -17.1% | 2022-02-24, From 2019-01-01 |
| 2018-12-31 | $78.42M | +10.3% | 2021-02-25, From 2018-01-01 |
| 2017-12-31 | $71.08M | -5.0% | 2020-02-25, From 2017-01-01 |
| 2016-12-31 | $74.85M | +20.4% | 2019-02-20, From 2016-01-01 |
| 2015-12-31 | $62.18M | +6.4% | 2018-02-26, From 2015-01-01 |
| 2014-12-31 | $58.44M | n/a | 2017-02-23, From 2014-01-01 |
EBITDA at similar companies
| Company | Year ended | EBITDA | Change YoY |
|---|---|---|---|
| Lantheus Holdings, Inc. (LNTH) | 2025-12-31 | $380.93M | -27.0% |
| QuidelOrtho Corp (QDEL) | 2025-12-28 | -$477.20M | n/m |
| Neogen Corp (NEOG) | 2026-05-31 | $94.70M | n/m |
| Myriad Genetics Inc (MYGN) | 2025-12-31 | -$333.50M | n/m |
| Idexx Laboratories Inc (IDXX) | 2025-12-31 | $1.51B | +19.6% |
| Intellia Therapeutics, Inc. (NTLA) | 2025-12-31 | -$431.22M | n/m |
| Alpha Teknova, Inc. (TKNO) | 2025-12-31 | -$10.63M | n/m |
| Immucell Corp (ICCC) | 2025-12-31 | $4.43M | +306.8% |
| Aspira Women's Health Inc. (AWHL) | 2025-12-31 | -$7.80M | n/m |
Compare LNTH, QDEL, NEOG, MYGN side by side · Screen every company in In Vitro & In Vivo Diagnostic Substances ↗